Position in ERAS
as of Jun 30, 2026
· filed Aug 14, 2026
Position Value
$75,614,187
-$120,996,759 QoQ
Shares Held
4,127,412
-66.0% QoQ
Ownership
1.18%
of shares outstanding
% of Portfolio
7.16%
of 13F equity value
Holder Rank
#16
of 255 holders
Holding Since
Jun 2024
9 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in ERAS Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026Vivo Capital, LLC holds $1,052,388,129 across 43 Biotechnology names. ERAS ranks #3 (7.2% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | TRVI |
Trevi Therapeutics, Inc.
|
5,094,668 | $95,015,558 | |
| 2 | PRAX |
Praxis Precision Medicines, Inc.
|
271,116 | $90,766,925 | |
| 3 | ERAS |
Erasca, Inc.
This page
|
4,127,412 | $75,614,187 | |
| 4 | AVBP |
ArriVent BioPharma, Inc.
|
1,682,097 | $58,436,049 | |
| 5 | ABVX |
Abivax S.A.
|
414,899 | $55,289,440 | |
| 6 | TNGX |
Tango Therapeutics, Inc.
|
1,379,769 | $43,131,578 | |
| 7 | CRVS |
Corvus Pharmaceuticals, Inc.
|
2,805,816 | $41,918,891 | |
| 8 | DRUG |
Bright Minds Biosciences Inc.
|
557,172 | $39,113,474 |
All Filings in ERAS
Export CSV
9 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $75,614,187 | 4,127,412 | Shares | Sole | 2026-08-14 | |
| 2026-03-31 | $196,610,946 | 12,151,480 | Shares | Sole | 2026-05-20 | |
| 2025-12-31 | $34,497,152 | 9,273,428 | Shares | Sole | 2026-02-13 | |
| 2025-09-30 | $20,216,073 | 9,273,428 | Shares | Sole | 2025-11-14 | |
| 2025-06-30 | $8,581,080 | 6,756,756 | Shares | Sole | 2025-08-14 | |
| 2025-03-31 | $9,256,755 | 6,756,756 | Shares | Sole | 2025-05-12 | |
| 2024-12-31 | $16,959,457 | 6,756,756 | Shares | Sole | 2025-02-13 | |
| 2024-09-30 | $18,445,943 | 6,756,756 | Shares | Sole | 2024-11-13 | |
| 2024-06-30 | $15,945,944 | 6,756,756 | Shares | Sole | 2024-08-14 | |
| No filing history on record for this holder in this stock. | ||||||